NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
0.9300
+0.0500 (5.68%)
Feb 9, 2026, 10:24 AM EST - Market open
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,160,745
Market Cap
20.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| IN8bio | 17 |
| VYNE Therapeutics | 13 |
| Genenta Science | 13 |
| FibroBiologics | 13 |
| Lexaria Bioscience | 7 |
| Intensity Therapeutics | 7 |
| Jupiter Neurosciences | 4 |
NNVC News
- 7 days ago - NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - Accesswire
- 27 days ago - NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 - Accesswire
- 2 months ago - NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Accesswire
- 3 months ago - NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position - Accesswire
- 3 months ago - NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 - Accesswire
- 3 months ago - NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Accesswire
- 3 months ago - NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Accesswire
- 3 months ago - NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Accesswire